Advertisement

Advertisement

Emil J Freireich, MD, FAACR, Honored With AACR Award for Lifetime Achievement in Cancer Research

The American Association for Cancer Research (AACR) recognized Emil J Freireich, MD, FAACR, with the 2019 AACR Award for Lifetime Achievement in Cancer Research...

OneOncology Announces Lee Schwartzberg, MD, FACP, as Chief Medical Officer

OneOncology, the national partnership of community oncologists, has announced that Lee Schwartzberg, MD, FACP, has been named Chief Medical Officer...

Issues in Oncology

FDA Oncology Center of Excellence Issues Annual Report

The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) has issued its 2018 Annual Report, including updates on regulatory reviews and initiatives...


Advertisement
Issues in Oncology

Physician Wellness: Time to Heal the Healer

Physician wellness is emblazoned upfront in the news with attention-seeking headlines on a daily basis. The fact that one or two physicians commit suicide every day...

The Skin Cancer Foundation Awards $125,000 in Research Grants

The Skin Cancer Foundation hosted its member reception on March 1 during the American Academy of Dermatology (AAD) Annual Meeting. As part of the reception...

Advertisement




More Top Stories

Leukemia
Immunotherapy

Stefan O. Ciurea, MD, on Infusing High Doses of Natural Killer Cells: An Enhanced Antitumor Effect

Bladder Cancer

Adjuvant Sequential Chemotherapy Plus Radiotherapy vs Radiotherapy Alone for Locally Advanced Bladder Cancer

A phase III Egyptian trial presented by Mohamad S. Zaghloul, MD, et al at the 2019 Genitourinary Cancers Symposium focused on the benefit of adjuvant chemotherapy in patients with locally advanced bladder cancer treated with postoperative radiotherapy.1 Researchers compared postoperative...

Advertisement

OPTIMISMM: Addition of Pomalidomide to Bortezomib/Dexamethasone in Pretreated Relapsed or Refractory Multiple Myeloma

In the phase III OPTIMISMM trial, reported by Richardson et al in The Lancet Oncology, researchers found that the addition of pomalidomide to bortezomib/dexamethasone improved progression-free survival in relapsed or refractory multiple myeloma previously treated with lenalidomide. Study Details...

Lung Cancer
Immunotherapy

Leora Horn, MD, on Small Cell Lung Cancer and Immuno-oncology: Have We Finally Solved the Small Cell Paradox?

Mark E. Thompson, MD, Named Medical Director for Public Policy at Community Oncology Alliance

The Community Oncology Alliance (COA) recently announced that Mark E. Thompson, MD, has been appointed to the newly created staff position of Medical Director for Public Policy. Dr. Thompson will chair the COA Government Affairs and Policy Committee, a standing committee that guides official...

Neuroendocrine Tumors
Immunotherapy

Dual-Immunotherapy Approach Shows Efficacy in High-Grade Neuroendocrine Tumors

COMBINING TWO established immunotherapy agents achieved tumor shrinkage in rare, aggressive, extrapancreatic high-grade neuroendocrine tumors, according to the results of SWOG S1609, a phase II clinical basket trial also known as DART (Dual Anti– CLTA-4 and Anti–PD-1 Blockade in Rare Tumors). The...

Early-Stage Study of Nivolumab Alone or in Combination With Cisplatin/Gemcitabine in Biliary Tract Cancer

In a Japanese phase I trial reported by Ueno et al in The Lancet Gastroenterology & Hepatology, researchers found nivolumab showed activity and had a manageable safety profile in patients with unresectable or recurrent biliary tract cancer. Methods The open-label phase I trial was conducted...

Breast Cancer
Immunotherapy

Elizabeth A. Mittendorf, MD, PhD, on Breast Cancer Immunotherapy: Building on Recent Successes

Breast Cancer

Postprogression Treatment of Estrogen Receptor–Positive Breast Cancer: Future Approaches

AT THE 2019 Miami Breast Cancer Conference, William J. Gradishar, MD, FASCO, presented a vision of the future in the treatment of advanced hormone receptor–positive breast cancer.1 The refinement of disease subsets, the development of agents targeting the PI3K/AKT/mTOR pathway, the use of novel...

Advertisement

ACCURE Trial: Improving Racial Disparities in Treatment for Patients With Early-Stage Lung and Breast Cancers

Results from a study published by Cykert et al in The Journal of the National Medical Association show that a pragmatic system-based intervention within cancer treatment centers can nearly eliminate existing disparities in treatment and outcomes for black patients with early-stage...